v3.25.2
Balance Sheet Components
 6 Months Ended 12 Months Ended
Jun. 30, 2025
Dec. 31, 2024
Disclosure Of Balance Sheet Components [Abstract]    
Balance Sheet Components
3. Balance Sheet Components
Prepaid Expenses and
Other Current
Assets
Prepaid expenses and
other current
assets
as of June 30, 2025 and
December 
31, 2024, consisted of the following (in thousands):
 
    
June 30, 2025
     
December 31, 2024
  
Prepaid foreign consumption tax
    $ —       $ 81  
Prepaid research and development costs
      6,362        57  
Other receivables
      99        83  
Prepaid other
      100        129  
  
 
 
     
 
 
  
Prepaid expenses and other current assets
    $ 6,561      $ 350  
  
 
 
     
 
 
  
Other
Non-Current
Assets
Other
non-current
assets as of June 30, 2025 and December 31, 2024, consisted of the following (in thousands):
 
    
June 30, 2025
     
December 31, 2024
  
Investment in Celexor
    $ 942      $ 942  
Non-current deposits
      69        69  
Property and equipment, net
      3        8  
  
 
 
     
 
 
  
Other non-current assets
    $ 1,014      $ 1,019  
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities as of June 30, 2025 and December 31, 2024, consisted of the following (in thousands):
 
    
June 30, 2025
     
December 31, 2024
  
Accrued research and development costs
    $ 1,469      $ 654  
Accrued compensation
      480        931  
Accrued professional fees
      88        485  
Accrued financing cost
      2,258        1,294  
Accrued other
      117        96  
  
 
 
     
 
 
  
Accrued expenses and other current liabilities
    $ 4,412      $ 3,460  
  
 
 
     
 
 
  
4. Balance Sheet Components
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets as of December 31, 2024 and 2023, consisted of the following (in thousands):
 
    
As of
December 31,
  
    
2024
     
2023
  
Prepaid foreign consumption tax
    $ 81      $ 98  
Prepaid research and development costs
      57        —   
Other receivables
      83        223  
Prepaid other
      129        106  
 
 
 
 
 
 
 
 
 
Prepaid expenses and other current assets
    $ 350      $ 427  
 
 
 
 
 
 
 
 
 
Other
Non-Current
Assets
Other
non-current
assets as of December 31, 2024 and 2023, consisted of the following (in thousands):
 
    
As of December 31,
  
    
2024
     
2023
  
Deferred offering costs
    $ 1,888      $ —   
Non-current
deposits
      69        123  
Investment in Celexor
      942        942  
 
 
 
 
 
 
 
 
 
Other
non-current
assets
    $ 2,899      $ 1,065  
 
 
 
 
 
 
 
 
 
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities as of December 31, 2024 and 2023, consisted of the following (in thousands):
 
    
As of December 31,
  
    
2024
     
2023
  
Accrued research and development costs
    $ 654      $ 785  
Accrued compensation
      931        1,006  
Accrued professional fees
      485        322  
Accrued financing cost
      1,294        —   
Accrued other
      96        880  
Foreign consumption tax payable
      —         137  
 
 
 
 
 
 
 
 
 
Accrued expenses and other current liabilities
    $ 3,460      $ 3,130